SCD-044 for Plaque Psoriasis
(SOLARES-PsO-1 Trial)

Recruiting in Palo Alto (17 mi)

+23 other locations

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 2

Waitlist Available

Sponsor: Sun Pharmaceutical Industries Limited

Prior Safety Data

Trial Summary

What is the purpose of this trial?

This trial is testing a new medication called SCD-044 to see if it can help people with moderate to severe plaque psoriasis. The study includes patients who have more serious forms of psoriasis that may not respond well to usual treatments. The goal is to find out if SCD-044 can reduce the symptoms of psoriasis.

Eligibility Criteria

This trial is for adults over 18 with moderate to severe plaque psoriasis, a skin condition characterized by scaly patches. Participants must have had the condition for at least 6 months and should not be pregnant or breastfeeding. They shouldn't have tuberculosis (TB) or need other psoriasis treatments during the study.

Inclusion Criteria

I have never had active TB nor shown symptoms of it.

I have had plaque psoriasis for over 6 months and am not pregnant or breastfeeding.

I am 18 years old or older.

Exclusion Criteria

My psoriasis is not the common plaque type but one of the more severe forms.

I expect to need treatment for my psoriasis during the trial.

I have had or currently have uveitis.

Treatment Details

Interventions

Placebo (Unknown)
SCD-044_Dose 1 (Unknown)
SCD-044_Dose 2 (Unknown)
SCD-044_Dose 3 (Unknown)

Trial OverviewThe study tests SCD-044 in three different doses compared to a placebo to see its effect on plaque psoriasis. It's conducted across multiple centers where participants are randomly assigned to receive either the drug or placebo without knowing which one they're getting.

Participant Groups

4Treatment groups

Active Control

Placebo Group

Group I: SCD-044 Tablets_Dose 1Active Control1 Intervention

SCD-044 tablets at Dose 1

Group II: SCD-044 Tablets_Dose 2Active Control1 Intervention

SCD-044 tablets at Dose 2

Group III: SCD-044 Tablets_Dose 3Active Control1 Intervention

SCD-044 tablets at Dose 3

Group IV: Placebo of SCD-044 productPlacebo Group1 Intervention

Placebo of SCD-044 study drug